Fennec Pharmaceuticals Inc.
FENC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 123.7% | 1,341.6% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.3% | 94.1% | 94.4% | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 10.1% | -58.2% | -1,471.5% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.9% | -75.5% | -1,544.9% | – |
| EPS Diluted | -0.016 | -0.6 | -0.95 | -0.67 |
| % Growth | 97.3% | 36.8% | -41.8% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |